参考文献（第2/3页）

［31］Arcila M E，et al．EGFR exon 20 insertion mutations in lung adenocarcinomas：prevalence，molecular heterogeneity，and clinicopathologic characteristics［J］．Mol Cancer Ther，2013，12（2）：220-229.

［32］Wang Y C，et al．Comparison of Cancer Incidence between China and the USA［J］．Cancer Biol Med，2012，9（2）：128-132.

［33］Topalian S L，et al．Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］．N Engl J Med，2012，366（26）：2443-2454.

［34］Seralini G E，et al．Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize［J］．Food Chem Toxicol，2012，50（11）：4221-4231.

［35］Lim S S，et al．A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010［J］．Lancet，2012，380（9859）：2224-2260.

［36］Govindan R，et al．Genomic landscape of non-small cell lung cancer in smokers and never-smokers［J］．Cell，2012，150（6）：1121-1134.

［37］An S J，et al．Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status［J］．PLoS One，2012，7（6）：e40109.

［38］Zava T T，Zava D T．Assessment of Japanese iodine intake based on seaweed consumption in Japan：A literature-based analysis［J］．Thyroid Res，2011，4：14.

［39］Wagle N，et al．Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling［J］．J Clin Oncol，2011，29（22）：3085-3096.

［40］Sequist L V，et al．Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］．Sci Transl Med，2011，3（75）：75ra26.

［41］Ramaekers B L，et al．Systematic review and meta-analysis of radiotherapy in various head and neck cancers：comparing photons，carbon-ions and protons［J］．Cancer Treat Rev，2011，37（3）：185-201.

［42］Pederson T，Mukherjee S．The Emperor of All Maladies A Biography of Cancer［J］．Science，2011，332（6028）：423-423.

［43］Moeller B J，et al．Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy［J］．Radiat Oncol，2011，6：58.

［44］Miller L H，Su X．Artemisinin：discovery from the Chinese herbal garden［J］．Cell，2011，146（6）：855-858.

［45］Kantoff W，et al．Sipuleucel-T immunotherapy for castration-resistant prostate cancer［J］．N Engl J Med，2010，363（5）：411-422.

［46］Domchek S M，et al．Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality［J］．JAMA，2010，304（9）：967-975.

［47］Sawka A M，et al．Second primary malignancy risk after radioactive iodine treatment for thyroid cancer：a systematic review and meta-analysis［J］．Thyroid，2009，19（5）：451-457.

［48］Little M P．Cancer and non-cancer effects in Japanese atomic bomb survivors［J］．J Radiol Prot，2009，29（2A）：A43-59.

［49］Lawenda B D，et al．Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy？［J］．J Natl Cancer Inst，2008，100（11）：773-783.

［50］Dishop M K，Kuruvilla S．Primary and metastatic lung tumors in the pediatric population：a review and 25-year experience at a large children's hospital［J］．Arch Pathol Lab Med，2008，132（7）：1079-1103.

［51］Ballen K K，et al．Collection and preservation of cord blood for personal use［J］．Biol Blood Marrow Transplant，2008，14（3）：356-363.

［52］Schoder H，Gonen M．Screening for cancer with PET and PET/CT：potential and limitations［J］．J Nucl Med，2007，48 Suppl 1：4S-18S.

［53］McLaughlin J R，et al．Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations：a case-control study［J］．Lancet Oncol，2007，8（1）：26-34.

［54］Kelly E，Russell S J．History of oncolytic viruses：genesis to genetic engineering［J］．Mol Ther，2007，15（4）：651-659.

［55］Eapen M，et al．Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia：a comparison study［J］．Lancet，2007，369（9577）：1947-1954.

［56］Bjelakovic G，et al．Mortality in randomized trials of antioxidant supplements for primary and secondary prevention：systematic review and meta-analysis［J］．JAMA，2007，297（8）：842-857.

［57］Pearse A M，Swift K．Allograft theory：transmission of devil facial-tumour disease［J］．Nature，2006，439（7076）：549.

［58］Murgia C，et al．Clonal origin and evolution of a transmissible cancer［J］．Cell，2006，126（3）：477-487.

［59］Garber K．China approves world's first oncolytic virus therapy for cancer treatment［J］．J Natl Cancer Inst，2006，98（5）：298-300.